The Hidden Data Errors Delay Healthcare for Millions of Americans
Network inaccuracy isn’t an inconvenience – it’s a public health crisis. The post The Hidden Data Errors Delay Healthcare for Millions of Americans appeared first on MedCity News.
Read More
GSK Gets FDA Approval for New Severe Asthma Drug With a Dosing Advantage
GSK’s Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK’s own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen. The post GSK Gets FDA Approval for New Severe Asthma…
With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen
FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections. The post With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen appeared…
Journalists Weigh In on Racial Trauma, Medicaid Expansion, and Opioid Settlements
KFF Health News Midwest correspondent Cara Anthony discussed healing from racial trauma on “America’s Heroes Group” on Sept. 20. Click here to watch Anthony on “America’s Heroes Group” Explore Anthony’s series on the topic, “Silence in Sikeston” KFF Health News contributor Andy Miller discussed Medicaid expansion in Georgia on WUGA’s “The Georgia Health Report” on Sept….
A Medicaid Per Capita Cap on the ACA Expansion Population: State by State Estimates
This analysis examines the potential impacts on states and Medicaid enrollees of implementing a per capita cap on the federal share of Medicaid spending for the ACA Medicaid expansion population only, which is another proposal that has been discussed by members of Congress.
It’s Only a Subsidy If You’re Poor
By KIM BELLARD Even though most ACA enrollees/would-be enrollees have made their 2026 enrollment decisions assuming the expanded premium subsidies are not going to be renewed, the renewal of those subsidies is not entirely dead. Last week the House narrowly passed an extension, relying on a discharge petition and 17 Republican Congressmen willing to go…
Listen: Why Do I Need Prior Authorization?
Listen in as “Life Kit” host Marielle Segarra and health reporter Sarah Boden untangle the red tape that can make the prior authorization process frustrating. When the doctor says you need a prescription or treatment, sometimes you need approval from your health insurance first. That’s called prior authorization. Without that sign-off, insurance won’t pay. What…
Natalie Schneider, Fort Health
Natalie Schneider is CEO of Fort Health, a relatively new entrant into the children’s mental health market. Fort Health’s modus operandi is to partner with (i.e. market via) pediatricians to recruit patients. They are delivering integrated care and something called collaborative care…a newer model that has more frequent and shorter interventions and is more affordable….
Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings
Novo Nordisk’s Wegovy achieved statistically significant improvement in a Phase 3 study in the fatty liver disease MASH. Based on these preliminary results, the company plans to seek U.S. and European Union approvals in this indication in 2025. The post Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA…
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology portfolio and expand its business prospects in the U.S. and Europe. The post Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor…